BRPI0708331A2 - compostos de pirimidinil sulfonamida que inibem a adesão leucocitária mediada por vla-4 - Google Patents

Info

Publication number

BRPI0708331A2

BRPI0708331A2 BRPI0708331-9A BRPI0708331A BRPI0708331A2 BR PI0708331 A2 BRPI0708331 A2 BR PI0708331A2 BR PI0708331 A BRPI0708331 A BR PI0708331A BR PI0708331 A2 BRPI0708331 A2 BR PI0708331A2

Authority

BR

Brazil

Prior art keywords

formula

compound

compound according

disease

diethylamino

Prior art date

2006-02-27

Links

• Espacenet
• Global Dossier
• Discuss

• 230000001404 mediated effect Effects 0.000 title claims abstract description 20
• 230000023404 leukocyte cell-cell adhesion Effects 0.000 title abstract description 11
• WJJBIYLGJUVNJX-UHFFFAOYSA-N pyrimidine-2-sulfonamide Chemical class NS(=O)(=O)C1=NC=CC=N1 WJJBIYLGJUVNJX-UHFFFAOYSA-N 0.000 title abstract description 3
• 150000001875 compounds Chemical class 0.000 claims abstract description 180
• 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 61
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 16
• 208000011231 Crohn disease Diseases 0.000 claims abstract description 12
• 230000002757 inflammatory effect Effects 0.000 claims abstract description 10
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 69
• 201000010099 disease Diseases 0.000 claims description 65
• 238000000034 method Methods 0.000 claims description 64
• -1 pyrimidin-4-ylamino Chemical group 0.000 claims description 61
• 150000003839 salts Chemical class 0.000 claims description 28
• 125000000217 alkyl group Chemical group 0.000 claims description 22
• 238000002360 preparation method Methods 0.000 claims description 20
• 125000006239 protecting group Chemical group 0.000 claims description 20
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
• 150000002148 esters Chemical class 0.000 claims description 16
• 239000008194 pharmaceutical composition Substances 0.000 claims description 16
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 15
• 125000003342 alkenyl group Chemical group 0.000 claims description 10
• 125000001188 haloalkyl group Chemical group 0.000 claims description 10
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 9
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 8
• 229910052799 carbon Inorganic materials 0.000 claims description 8
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
• 125000000304 alkynyl group Chemical group 0.000 claims description 7
• 239000003937 drug carrier Substances 0.000 claims description 7
• 150000002576 ketones Chemical class 0.000 claims description 7
• 108010041012 Integrin alpha4 Proteins 0.000 claims description 6
• 241000124008 Mammalia Species 0.000 claims description 6
• 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims description 6
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 5
• 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 5
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
• HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims description 4
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
• 150000004820 halides Chemical class 0.000 claims description 4
• 150000001299 aldehydes Chemical class 0.000 claims description 3
• 238000005576 amination reaction Methods 0.000 claims description 3
• VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 claims description 3
• 235000019260 propionic acid Nutrition 0.000 claims description 3
• 239000002168 alkylating agent Substances 0.000 claims description 2
• 229940100198 alkylating agent Drugs 0.000 claims description 2
• DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims description 2
• QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 claims description 2
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
• 125000001475 halogen functional group Chemical group 0.000 claims 2
• JJOWVQRSSFANTK-QHCPKHFHSA-N (2s)-2-[[2-(diethylamino)-5-[ethyl(2-methylpropylsulfonyl)amino]pyrimidin-4-yl]amino]-3-[4-(pyrrolidine-1-carbonyloxy)phenyl]propanoic acid Chemical compound CCN(CC)C1=NC=C(N(CC)S(=O)(=O)CC(C)C)C(N[C@@H](CC=2C=CC(OC(=O)N3CCCC3)=CC=2)C(O)=O)=N1 JJOWVQRSSFANTK-QHCPKHFHSA-N 0.000 claims 1
• LLYUGVGQHYKTPB-NRFANRHFSA-N (2s)-2-[[2-(diethylamino)-5-[ethyl(3,3,3-trifluoropropylsulfonyl)amino]pyrimidin-4-yl]amino]-3-[4-(pyrrolidine-1-carbonyloxy)phenyl]propanoic acid Chemical compound CCN(CC)C1=NC=C(N(CC)S(=O)(=O)CCC(F)(F)F)C(N[C@@H](CC=2C=CC(OC(=O)N3CCCC3)=CC=2)C(O)=O)=N1 LLYUGVGQHYKTPB-NRFANRHFSA-N 0.000 claims 1
• YZONLLBMLHKUFN-IBGZPJMESA-N (2s)-2-[[2-(diethylamino)-5-[ethyl(trifluoromethylsulfonyl)amino]pyrimidin-4-yl]amino]-3-[4-(pyrrolidine-1-carbonyloxy)phenyl]propanoic acid Chemical compound CCN(CC)C1=NC=C(N(CC)S(=O)(=O)C(F)(F)F)C(N[C@@H](CC=2C=CC(OC(=O)N3CCCC3)=CC=2)C(O)=O)=N1 YZONLLBMLHKUFN-IBGZPJMESA-N 0.000 claims 1
• SWLRXLYNAHKZOI-QHCPKHFHSA-N (2s)-2-[[5-[butylsulfonyl(ethyl)amino]-2-(diethylamino)pyrimidin-4-yl]amino]-3-[4-(pyrrolidine-1-carbonyloxy)phenyl]propanoic acid Chemical compound CCCCS(=O)(=O)N(CC)C1=CN=C(N(CC)CC)N=C1N[C@H](C(O)=O)CC(C=C1)=CC=C1OC(=O)N1CCCC1 SWLRXLYNAHKZOI-QHCPKHFHSA-N 0.000 claims 1
• 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims 1
• FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims 1
• 230000006472 autoimmune response Effects 0.000 claims 1
• 108010008212 Integrin alpha4beta1 Proteins 0.000 abstract description 27
• 238000011282 treatment Methods 0.000 abstract description 27
• 241001465754 Metazoa Species 0.000 abstract description 18
• 208000006673 asthma Diseases 0.000 abstract description 14
• 206010028980 Neoplasm Diseases 0.000 abstract description 11
• 206010039073 rheumatoid arthritis Diseases 0.000 abstract description 11
• 208000027866 inflammatory disease Diseases 0.000 abstract description 6
• 201000001320 Atherosclerosis Diseases 0.000 abstract description 5
• 206010027476 Metastases Diseases 0.000 abstract description 5
• 238000002054 transplantation Methods 0.000 abstract description 5
• 208000030507 AIDS Diseases 0.000 abstract description 4
• 208000024827 Alzheimer disease Diseases 0.000 abstract description 4
• 206010012289 Dementia Diseases 0.000 abstract description 4
• 206010012601 diabetes mellitus Diseases 0.000 abstract description 4
• 230000009401 metastasis Effects 0.000 abstract description 4
• 208000031225 myocardial ischemia Diseases 0.000 abstract description 4
• 208000014644 Brain disease Diseases 0.000 abstract description 3
• 239000000203 mixture Substances 0.000 description 93
• 238000006243 chemical reaction Methods 0.000 description 60
• 239000000243 solution Substances 0.000 description 50
• 210000004027 cell Anatomy 0.000 description 48
• AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 46
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 42
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 40
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 35
• 238000009472 formulation Methods 0.000 description 35
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 32
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
• 239000003814 drug Substances 0.000 description 24
• 239000004480 active ingredient Substances 0.000 description 23
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 22
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
• 241000700159 Rattus Species 0.000 description 20
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
• 230000006378 damage Effects 0.000 description 18
• 229940079593 drug Drugs 0.000 description 18
• 108010044426 integrins Proteins 0.000 description 18
• 102000006495 integrins Human genes 0.000 description 18
• 239000002253 acid Substances 0.000 description 17
• 239000011780 sodium chloride Substances 0.000 description 17
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
• 208000016192 Demyelinating disease Diseases 0.000 description 16
• 150000001412 amines Chemical class 0.000 description 16
• 238000007796 conventional method Methods 0.000 description 16
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 15
• 241000699670 Mus sp. Species 0.000 description 15
• 235000019439 ethyl acetate Nutrition 0.000 description 15
• 229910052739 hydrogen Inorganic materials 0.000 description 15
• 239000003921 oil Substances 0.000 description 15
• 235000019198 oils Nutrition 0.000 description 15
• 239000007787 solid Substances 0.000 description 15
• 206010012305 Demyelination Diseases 0.000 description 14
• 239000001257 hydrogen Substances 0.000 description 14
• 238000001556 precipitation Methods 0.000 description 14
• 239000000047 product Substances 0.000 description 14
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 13
• 238000003556 assay Methods 0.000 description 13
• 239000002585 base Substances 0.000 description 13
• 238000004587 chromatography analysis Methods 0.000 description 13
• 238000000746 purification Methods 0.000 description 13
• 210000001519 tissue Anatomy 0.000 description 13
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
• 229940126062 Compound A Drugs 0.000 description 12
• NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 12
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
• 230000027455 binding Effects 0.000 description 12
• 238000001704 evaporation Methods 0.000 description 12
• 230000008020 evaporation Effects 0.000 description 12
• 238000000605 extraction Methods 0.000 description 12
• 238000001914 filtration Methods 0.000 description 12
• 210000000265 leukocyte Anatomy 0.000 description 12
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
• 238000006386 neutralization reaction Methods 0.000 description 12
• 238000004809 thin layer chromatography Methods 0.000 description 12
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
• 238000010171 animal model Methods 0.000 description 11
• 239000004615 ingredient Substances 0.000 description 11
• 238000001990 intravenous administration Methods 0.000 description 11
• 230000000750 progressive effect Effects 0.000 description 11
• 239000002904 solvent Substances 0.000 description 11
• 208000024891 symptom Diseases 0.000 description 11
• 206010061218 Inflammation Diseases 0.000 description 10
• 230000001154 acute effect Effects 0.000 description 10
• 239000000460 chlorine Substances 0.000 description 10
• 238000001727 in vivo Methods 0.000 description 10
• 230000004054 inflammatory process Effects 0.000 description 10
• 239000002953 phosphate buffered saline Substances 0.000 description 10
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
• 230000009467 reduction Effects 0.000 description 10
• 238000006722 reduction reaction Methods 0.000 description 10
• 210000002966 serum Anatomy 0.000 description 10
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
• 239000003981 vehicle Substances 0.000 description 10
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 9
• 108010067306 Fibronectins Proteins 0.000 description 9
• 102000016359 Fibronectins Human genes 0.000 description 9
• 238000002955 isolation Methods 0.000 description 9
• 239000000463 material Substances 0.000 description 9
• 239000000741 silica gel Substances 0.000 description 9
• 229910002027 silica gel Inorganic materials 0.000 description 9
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 9
• 238000012360 testing method Methods 0.000 description 9
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
• 102000012153 HLA-B27 Antigen Human genes 0.000 description 8
• 108010061486 HLA-B27 Antigen Proteins 0.000 description 8
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 8
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
• 229920002472 Starch Polymers 0.000 description 8
• 239000000443 aerosol Substances 0.000 description 8
• 238000004458 analytical method Methods 0.000 description 8
• 206010003246 arthritis Diseases 0.000 description 8
• 210000004369 blood Anatomy 0.000 description 8
• 239000008280 blood Substances 0.000 description 8
• 239000000872 buffer Substances 0.000 description 8
• 230000001684 chronic effect Effects 0.000 description 8
• 230000000694 effects Effects 0.000 description 8
• 230000005764 inhibitory process Effects 0.000 description 8
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
• 229910052757 nitrogen Inorganic materials 0.000 description 8
• 239000000546 pharmaceutical excipient Substances 0.000 description 8
• 235000019698 starch Nutrition 0.000 description 8
• 208000011580 syndromic disease Diseases 0.000 description 8
• 239000003826 tablet Substances 0.000 description 8
• WQRWVWWUVJMCFW-FQEVSTJZSA-N (2s)-2-[[2-(diethylamino)-5-[ethyl(methylsulfonyl)amino]pyrimidin-4-yl]amino]-3-[4-(pyrrolidine-1-carbonyloxy)phenyl]propanoic acid Chemical compound CCN(CC)C1=NC=C(N(CC)S(C)(=O)=O)C(N[C@@H](CC=2C=CC(OC(=O)N3CCCC3)=CC=2)C(O)=O)=N1 WQRWVWWUVJMCFW-FQEVSTJZSA-N 0.000 description 7
• 238000005160 1H NMR spectroscopy Methods 0.000 description 7
• 206010009900 Colitis ulcerative Diseases 0.000 description 7
• 208000009386 Experimental Arthritis Diseases 0.000 description 7
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 7
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
• 201000006704 Ulcerative Colitis Diseases 0.000 description 7
• 125000004432 carbon atom Chemical group C* 0.000 description 7
• 239000003795 chemical substances by application Substances 0.000 description 7
• 206010009887 colitis Diseases 0.000 description 7
• 238000011161 development Methods 0.000 description 7
• 210000002889 endothelial cell Anatomy 0.000 description 7
• 238000002347 injection Methods 0.000 description 7
• 239000007924 injection Substances 0.000 description 7
• 230000000306 recurrent effect Effects 0.000 description 7
• 230000004044 response Effects 0.000 description 7
• 239000008107 starch Substances 0.000 description 7
• 239000000725 suspension Substances 0.000 description 7
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 6
• IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 6
• 102000008186 Collagen Human genes 0.000 description 6
• 108010035532 Collagen Proteins 0.000 description 6
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
• 201000009906 Meningitis Diseases 0.000 description 6
• 102000006386 Myelin Proteins Human genes 0.000 description 6
• 108010083674 Myelin Proteins Proteins 0.000 description 6
• 206010033799 Paralysis Diseases 0.000 description 6
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
• MMFCRWJFCGYGKT-QHCPKHFHSA-N [4-[(2s)-2-[[2-(diethylamino)-5-(propan-2-ylamino)pyrimidin-4-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-3-oxopropyl]phenyl] pyrrolidine-1-carboxylate Chemical compound CCN(CC)C1=NC=C(NC(C)C)C(N[C@@H](CC=2C=CC(OC(=O)N3CCCC3)=CC=2)C(=O)OC(C)(C)C)=N1 MMFCRWJFCGYGKT-QHCPKHFHSA-N 0.000 description 6
• 239000000427 antigen Substances 0.000 description 6
• 102000036639 antigens Human genes 0.000 description 6
• 108091007433 antigens Proteins 0.000 description 6
• 201000011510 cancer Diseases 0.000 description 6
• 239000002775 capsule Substances 0.000 description 6
• 239000003054 catalyst Substances 0.000 description 6
• 235000015165 citric acid Nutrition 0.000 description 6
• 229920001436 collagen Polymers 0.000 description 6
• 210000001072 colon Anatomy 0.000 description 6
• 230000002354 daily effect Effects 0.000 description 6
• 235000019253 formic acid Nutrition 0.000 description 6
• 125000005843 halogen group Chemical group 0.000 description 6
• 238000004128 high performance liquid chromatography Methods 0.000 description 6
• 210000002540 macrophage Anatomy 0.000 description 6
• 235000019359 magnesium stearate Nutrition 0.000 description 6
• 238000002156 mixing Methods 0.000 description 6
• 239000013641 positive control Substances 0.000 description 6
• 239000011541 reaction mixture Substances 0.000 description 6
• 102000005962 receptors Human genes 0.000 description 6
• 108020003175 receptors Proteins 0.000 description 6
• 125000003107 substituted aryl group Chemical group 0.000 description 6
• 230000001225 therapeutic effect Effects 0.000 description 6
• 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 5
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 5
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 5
• 239000007995 HEPES buffer Substances 0.000 description 5
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
• 229960000583 acetic acid Drugs 0.000 description 5
• 150000007513 acids Chemical class 0.000 description 5
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
• 230000015572 biosynthetic process Effects 0.000 description 5
• 230000008499 blood brain barrier function Effects 0.000 description 5
• 210000001218 blood-brain barrier Anatomy 0.000 description 5
• 239000012267 brine Substances 0.000 description 5
• 210000003169 central nervous system Anatomy 0.000 description 5
• 239000003153 chemical reaction reagent Substances 0.000 description 5
• 239000012043 crude product Substances 0.000 description 5
• 125000000392 cycloalkenyl group Chemical group 0.000 description 5
• 230000003210 demyelinating effect Effects 0.000 description 5
• 230000001419 dependent effect Effects 0.000 description 5
• 206010014599 encephalitis Diseases 0.000 description 5
• 239000007903 gelatin capsule Substances 0.000 description 5
• 238000000338 in vitro Methods 0.000 description 5
• 239000000543 intermediate Substances 0.000 description 5
• FTCYIGBVOHNHCD-UHFFFAOYSA-N isaxonine Chemical compound CC(C)NC1=NC=CC=N1 FTCYIGBVOHNHCD-UHFFFAOYSA-N 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 210000000056 organ Anatomy 0.000 description 5
• KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
• 229910000027 potassium carbonate Inorganic materials 0.000 description 5
• 239000003586 protic polar solvent Substances 0.000 description 5
• 238000011084 recovery Methods 0.000 description 5
• 238000006268 reductive amination reaction Methods 0.000 description 5
• 230000002829 reductive effect Effects 0.000 description 5
• 239000011734 sodium Substances 0.000 description 5
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
• 235000017557 sodium bicarbonate Nutrition 0.000 description 5
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
• 238000007920 subcutaneous administration Methods 0.000 description 5
• 125000001424 substituent group Chemical group 0.000 description 5
• SDRNIMLNYYTUKR-NRFANRHFSA-N (2s)-2-[[2-(diethylamino)-5-[methylsulfonyl(propan-2-yl)amino]pyrimidin-4-yl]amino]-3-[4-(pyrrolidine-1-carbonyloxy)phenyl]propanoic acid Chemical compound CCN(CC)C1=NC=C(N(C(C)C)S(C)(=O)=O)C(N[C@@H](CC=2C=CC(OC(=O)N3CCCC3)=CC=2)C(O)=O)=N1 SDRNIMLNYYTUKR-NRFANRHFSA-N 0.000 description 4
• 208000023275 Autoimmune disease Diseases 0.000 description 4
• 102000000844 Cell Surface Receptors Human genes 0.000 description 4
• 108010001857 Cell Surface Receptors Proteins 0.000 description 4
• 239000012981 Hank's balanced salt solution Substances 0.000 description 4
• OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
• 241000699666 Mus <mouse, genus> Species 0.000 description 4
• 241000699660 Mus musculus Species 0.000 description 4
• 238000005481 NMR spectroscopy Methods 0.000 description 4
• 210000001744 T-lymphocyte Anatomy 0.000 description 4
• 239000002671 adjuvant Substances 0.000 description 4
• 239000013566 allergen Substances 0.000 description 4
• PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 4
• 150000005005 aminopyrimidines Chemical class 0.000 description 4
• 210000003423 ankle Anatomy 0.000 description 4
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
• 230000037396 body weight Effects 0.000 description 4
• 239000001768 carboxy methyl cellulose Substances 0.000 description 4
• 238000010790 dilution Methods 0.000 description 4
• 239000012895 dilution Substances 0.000 description 4
• 235000019441 ethanol Nutrition 0.000 description 4
• 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 4
• 238000003818 flash chromatography Methods 0.000 description 4
• 208000024908 graft versus host disease Diseases 0.000 description 4
• 239000012535 impurity Substances 0.000 description 4
• 239000003701 inert diluent Substances 0.000 description 4
• 230000004968 inflammatory condition Effects 0.000 description 4
• 238000001802 infusion Methods 0.000 description 4
• 230000003993 interaction Effects 0.000 description 4
• 210000001503 joint Anatomy 0.000 description 4
• 210000003127 knee Anatomy 0.000 description 4
• 239000010410 layer Substances 0.000 description 4
• 210000004698 lymphocyte Anatomy 0.000 description 4
• 230000014759 maintenance of location Effects 0.000 description 4
• 210000005012 myelin Anatomy 0.000 description 4
• 239000012044 organic layer Substances 0.000 description 4
• 239000001301 oxygen Substances 0.000 description 4
• 229910052760 oxygen Inorganic materials 0.000 description 4
• 239000002245 particle Substances 0.000 description 4
• 235000011007 phosphoric acid Nutrition 0.000 description 4
• FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 4
• 239000006187 pill Substances 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 150000003141 primary amines Chemical class 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 108090000623 proteins and genes Proteins 0.000 description 4
• 102000004169 proteins and genes Human genes 0.000 description 4
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
• 230000000717 retained effect Effects 0.000 description 4
• 238000013207 serial dilution Methods 0.000 description 4
• 239000000377 silicon dioxide Substances 0.000 description 4
• 210000003491 skin Anatomy 0.000 description 4
• 238000001356 surgical procedure Methods 0.000 description 4
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
• 238000011830 transgenic mouse model Methods 0.000 description 4
• UJURHSUDCZMQEN-QHCPKHFHSA-N (2s)-2-[[5-[cyclopentyl(methylsulfonyl)amino]-2-(diethylamino)pyrimidin-4-yl]amino]-3-[4-(pyrrolidine-1-carbonyloxy)phenyl]propanoic acid Chemical compound N([C@@H](CC=1C=CC(OC(=O)N2CCCC2)=CC=1)C(O)=O)C1=NC(N(CC)CC)=NC=C1N(S(C)(=O)=O)C1CCCC1 UJURHSUDCZMQEN-QHCPKHFHSA-N 0.000 description 3
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
• 208000004998 Abdominal Pain Diseases 0.000 description 3
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 3
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
• 101100167062 Caenorhabditis elegans chch-3 gene Proteins 0.000 description 3
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
• 206010008909 Chronic Hepatitis Diseases 0.000 description 3
• 108090000695 Cytokines Proteins 0.000 description 3
• 102000004127 Cytokines Human genes 0.000 description 3
• 206010012438 Dermatitis atopic Diseases 0.000 description 3
• 206010012735 Diarrhoea Diseases 0.000 description 3
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 101001002508 Homo sapiens Immunoglobulin-binding protein 1 Proteins 0.000 description 3
• 102100021042 Immunoglobulin-binding protein 1 Human genes 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• 206010030113 Oedema Diseases 0.000 description 3
• 108010058846 Ovalbumin Proteins 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• 102000035195 Peptidases Human genes 0.000 description 3
• 108091005804 Peptidases Proteins 0.000 description 3
• 206010036105 Polyneuropathy Diseases 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 201000004681 Psoriasis Diseases 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• 206010038910 Retinitis Diseases 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 208000006011 Stroke Diseases 0.000 description 3
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
• 208000030886 Traumatic Brain injury Diseases 0.000 description 3
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
• 230000002159 abnormal effect Effects 0.000 description 3
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
• 125000003277 amino group Chemical group 0.000 description 3
• 201000008937 atopic dermatitis Diseases 0.000 description 3
• 230000001363 autoimmune Effects 0.000 description 3
• 210000000988 bone and bone Anatomy 0.000 description 3
• 239000011575 calcium Substances 0.000 description 3
• 229910052791 calcium Inorganic materials 0.000 description 3
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
• 210000000845 cartilage Anatomy 0.000 description 3
• 229910052801 chlorine Inorganic materials 0.000 description 3
• 230000002950 deficient Effects 0.000 description 3
• 238000012217 deletion Methods 0.000 description 3
• 230000037430 deletion Effects 0.000 description 3
• 230000009266 disease activity Effects 0.000 description 3
• 208000035475 disorder Diseases 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 231100000673 dose–response relationship Toxicity 0.000 description 3
• 229960001484 edetic acid Drugs 0.000 description 3
• 239000003480 eluent Substances 0.000 description 3
• 210000003979 eosinophil Anatomy 0.000 description 3
• 230000001200 fecal consistency Effects 0.000 description 3
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
• 239000006260 foam Substances 0.000 description 3
• 239000012458 free base Substances 0.000 description 3
• 125000000524 functional group Chemical group 0.000 description 3
• 108020001507 fusion proteins Proteins 0.000 description 3
• 102000037865 fusion proteins Human genes 0.000 description 3
• 210000001035 gastrointestinal tract Anatomy 0.000 description 3
• 208000006454 hepatitis Diseases 0.000 description 3
• 210000000548 hind-foot Anatomy 0.000 description 3
• 125000001183 hydrocarbyl group Chemical group 0.000 description 3
• 230000028993 immune response Effects 0.000 description 3
• 238000011534 incubation Methods 0.000 description 3
• 239000012442 inert solvent Substances 0.000 description 3
• 230000006749 inflammatory damage Effects 0.000 description 3
• 230000028709 inflammatory response Effects 0.000 description 3
• 238000007912 intraperitoneal administration Methods 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 239000003446 ligand Substances 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 231100000516 lung damage Toxicity 0.000 description 3
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
• 235000019341 magnesium sulphate Nutrition 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
• 239000006199 nebulizer Substances 0.000 description 3
• 201000008383 nephritis Diseases 0.000 description 3
• WFSXMMJKDGCFJJ-UHFFFAOYSA-N nitro carbamate Chemical compound NC(=O)O[N+]([O-])=O WFSXMMJKDGCFJJ-UHFFFAOYSA-N 0.000 description 3
• 229940092253 ovalbumin Drugs 0.000 description 3
• 229910052763 palladium Inorganic materials 0.000 description 3
• 230000007824 polyneuropathy Effects 0.000 description 3
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
• 229920000053 polysorbate 80 Polymers 0.000 description 3
• 239000002244 precipitate Substances 0.000 description 3
• 235000019833 protease Nutrition 0.000 description 3
• 230000005855 radiation Effects 0.000 description 3
• 238000012453 sprague-dawley rat model Methods 0.000 description 3
• 239000011550 stock solution Substances 0.000 description 3
• 239000011975 tartaric acid Substances 0.000 description 3
• 235000002906 tartaric acid Nutrition 0.000 description 3
• 150000003892 tartrate salts Chemical class 0.000 description 3
• 229940124597 therapeutic agent Drugs 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
• 238000005303 weighing Methods 0.000 description 3
• 208000016261 weight loss Diseases 0.000 description 3
• 230000004580 weight loss Effects 0.000 description 3
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• NOYDQGFVFOQSAJ-UHFFFAOYSA-N 5-nitropyrimidine Chemical compound [O-][N+](=O)C1=CN=CN=C1 NOYDQGFVFOQSAJ-UHFFFAOYSA-N 0.000 description 2
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
• 241000244188 Ascaris suum Species 0.000 description 2
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
• LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
• 102000000503 Collagen Type II Human genes 0.000 description 2
• 108010041390 Collagen Type II Proteins 0.000 description 2
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
• OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 206010015226 Erythema nodosum Diseases 0.000 description 2
• 241000400611 Eucalyptus deanei Species 0.000 description 2
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 206010020751 Hypersensitivity Diseases 0.000 description 2
• 102000007547 Laminin Human genes 0.000 description 2
• 108010085895 Laminin Proteins 0.000 description 2
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
• 229930195725 Mannitol Natural products 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
• 235000009421 Myristica fragrans Nutrition 0.000 description 2
• 208000003435 Optic Neuritis Diseases 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 206010053869 POEMS syndrome Diseases 0.000 description 2
• 241001111421 Pannus Species 0.000 description 2
• 241001494479 Pecora Species 0.000 description 2
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
• LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
• 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• GSKPIENGCMJXAS-NRFANRHFSA-N [4-[(2s)-2-[[2-(diethylamino)-5-(methanesulfonamido)pyrimidin-4-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-3-oxopropyl]phenyl] pyrrolidine-1-carboxylate Chemical compound CCN(CC)C1=NC=C(NS(C)(=O)=O)C(N[C@@H](CC=2C=CC(OC(=O)N3CCCC3)=CC=2)C(=O)OC(C)(C)C)=N1 GSKPIENGCMJXAS-NRFANRHFSA-N 0.000 description 2
• QSZMBMQDIHAPQN-DEOSSOPVSA-N [4-[(2s)-2-[[2-(diethylamino)-5-[methylsulfonyl(prop-2-ynyl)amino]pyrimidin-4-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-3-oxopropyl]phenyl] pyrrolidine-1-carboxylate Chemical compound CCN(CC)C1=NC=C(N(CC#C)S(C)(=O)=O)C(N[C@@H](CC=2C=CC(OC(=O)N3CCCC3)=CC=2)C(=O)OC(C)(C)C)=N1 QSZMBMQDIHAPQN-DEOSSOPVSA-N 0.000 description 2
• 230000005856 abnormality Effects 0.000 description 2
• 206010000269 abscess Diseases 0.000 description 2
• 239000006096 absorbing agent Substances 0.000 description 2
• 238000009825 accumulation Methods 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 239000011149 active material Substances 0.000 description 2
• YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 2
• 230000001464 adherent effect Effects 0.000 description 2
• 230000010062 adhesion mechanism Effects 0.000 description 2
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
• 230000036428 airway hyperreactivity Effects 0.000 description 2
• 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
• 230000000735 allogeneic effect Effects 0.000 description 2
• 229910052782 aluminium Inorganic materials 0.000 description 2
• 230000003042 antagnostic effect Effects 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 210000001367 artery Anatomy 0.000 description 2
• 210000000544 articulatio talocruralis Anatomy 0.000 description 2
• 239000012911 assay medium Substances 0.000 description 2
• 210000001130 astrocyte Anatomy 0.000 description 2
• 230000003376 axonal effect Effects 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 238000001574 biopsy Methods 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 210000004204 blood vessel Anatomy 0.000 description 2
• 238000011685 brown norway rat Methods 0.000 description 2
• 239000007853 buffer solution Substances 0.000 description 2
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
• BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 2
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
• 150000001768 cations Chemical class 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 235000010980 cellulose Nutrition 0.000 description 2
• 229940125904 compound 1 Drugs 0.000 description 2
• 229940125782 compound 2 Drugs 0.000 description 2
• 229940126214 compound 3 Drugs 0.000 description 2
• 150000004696 coordination complex Chemical class 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 230000006735 deficit Effects 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 239000008121 dextrose Substances 0.000 description 2
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• 229940112141 dry powder inhaler Drugs 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 230000003511 endothelial effect Effects 0.000 description 2
• 210000003038 endothelium Anatomy 0.000 description 2
• 230000002349 favourable effect Effects 0.000 description 2
• 239000012091 fetal bovine serum Substances 0.000 description 2
• 239000000706 filtrate Substances 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 239000011737 fluorine Substances 0.000 description 2
• 229910052731 fluorine Inorganic materials 0.000 description 2
• 210000002683 foot Anatomy 0.000 description 2
• 210000002196 fr. b Anatomy 0.000 description 2
• 210000003918 fraction a Anatomy 0.000 description 2
• 210000000540 fraction c Anatomy 0.000 description 2
• KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 125000001072 heteroaryl group Chemical group 0.000 description 2
• 125000000623 heterocyclic group Chemical group 0.000 description 2
• 239000000833 heterodimer Substances 0.000 description 2
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
• 238000005984 hydrogenation reaction Methods 0.000 description 2
• 210000002865 immune cell Anatomy 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 230000001976 improved effect Effects 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 238000000099 in vitro assay Methods 0.000 description 2
• 208000016245 inborn errors of metabolism Diseases 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 230000000977 initiatory effect Effects 0.000 description 2
• 150000007529 inorganic bases Chemical class 0.000 description 2
• 230000003434 inspiratory effect Effects 0.000 description 2
• 210000002429 large intestine Anatomy 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 239000001115 mace Substances 0.000 description 2
• 239000011777 magnesium Substances 0.000 description 2
• 229910052749 magnesium Inorganic materials 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
• 239000011976 maleic acid Substances 0.000 description 2
• 239000000594 mannitol Substances 0.000 description 2
• 235000010355 mannitol Nutrition 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 238000002483 medication Methods 0.000 description 2
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
• 239000008108 microcrystalline cellulose Substances 0.000 description 2
• 229940016286 microcrystalline cellulose Drugs 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 239000012452 mother liquor Substances 0.000 description 2
• 206010065579 multifocal motor neuropathy Diseases 0.000 description 2
• 210000000440 neutrophil Anatomy 0.000 description 2
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 210000004789 organ system Anatomy 0.000 description 2
• 239000003960 organic solvent Substances 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
• 239000008177 pharmaceutical agent Substances 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 229920003023 plastic Polymers 0.000 description 2
• 239000004033 plastic Substances 0.000 description 2
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• 229960003975 potassium Drugs 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 238000003521 protein stability assay Methods 0.000 description 2
• FVLAYJRLBLHIPV-UHFFFAOYSA-N pyrimidin-5-amine Chemical compound NC1=CN=CN=C1 FVLAYJRLBLHIPV-UHFFFAOYSA-N 0.000 description 2
• 210000000664 rectum Anatomy 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 239000000523 sample Substances 0.000 description 2
• 150000003335 secondary amines Chemical class 0.000 description 2
• 210000000813 small intestine Anatomy 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• NKAAEMMYHLFEFN-ZVGUSBNCSA-M sodium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound [Na+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O NKAAEMMYHLFEFN-ZVGUSBNCSA-M 0.000 description 2
• 239000008247 solid mixture Substances 0.000 description 2
• 239000007858 starting material Substances 0.000 description 2
• 238000003756 stirring Methods 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
• 239000006228 supernatant Substances 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
• 230000000451 tissue damage Effects 0.000 description 2
• 231100000827 tissue damage Toxicity 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
• XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 2
• QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
• GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
• QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
• AGRIQBHIKABLPJ-UHFFFAOYSA-N 1-Pyrrolidinecarboxaldehyde Chemical compound O=CN1CCCC1 AGRIQBHIKABLPJ-UHFFFAOYSA-N 0.000 description 1
• RGCKYCDHTBQFKQ-UHFFFAOYSA-N 2,2,2-trifluoro-n-(2h-pyrimidin-1-yl)acetamide Chemical compound FC(F)(F)C(=O)NN1CN=CC=C1 RGCKYCDHTBQFKQ-UHFFFAOYSA-N 0.000 description 1
• OBTZDIRUQWFRFZ-UHFFFAOYSA-N 2-(5-methylfuran-2-yl)-n-(4-methylphenyl)quinoline-4-carboxamide Chemical compound O1C(C)=CC=C1C1=CC(C(=O)NC=2C=CC(C)=CC=2)=C(C=CC=C2)C2=N1 OBTZDIRUQWFRFZ-UHFFFAOYSA-N 0.000 description 1
• KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
• UQOKRDJILZMZKU-UHFFFAOYSA-N 2-nitropyrimidine Chemical compound [O-][N+](=O)C1=NC=CC=N1 UQOKRDJILZMZKU-UHFFFAOYSA-N 0.000 description 1
• AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• FVWYWFAOMUKQCF-UHFFFAOYSA-N 4-N,6-N-di(propan-2-yl)pyrimidine-4,6-diamine Chemical compound C(C)(C)NC1=CC(=NC=N1)NC(C)C FVWYWFAOMUKQCF-UHFFFAOYSA-N 0.000 description 1
• RJCHCFQTUKAYAA-UHFFFAOYSA-N 5-[[2-amino-5-[(4-methoxyphenyl)methyl]-3-methylimidazol-4-yl]methyl]-2-methoxybenzene-1,3-diol Chemical group C1=CC(OC)=CC=C1CC1=C(CC=2C=C(O)C(OC)=C(O)C=2)N(C)C(=N)N1 RJCHCFQTUKAYAA-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
• 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 241001156002 Anthonomus pomorum Species 0.000 description 1
• 206010002921 Aortitis Diseases 0.000 description 1
• 241000913992 Aprion Species 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 206010003497 Asphyxia Diseases 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 206010003591 Ataxia Diseases 0.000 description 1
• 206010071576 Autoimmune aplastic anaemia Diseases 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• 108010087504 Beta-Globulins Proteins 0.000 description 1
• 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 208000019838 Blood disease Diseases 0.000 description 1
• 208000006386 Bone Resorption Diseases 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• YRMCNNVPXMGPQC-UHFFFAOYSA-N CC(C)NC1=NC(=NC=C1)NC(=O)O Chemical compound CC(C)NC1=NC(=NC=C1)NC(=O)O YRMCNNVPXMGPQC-UHFFFAOYSA-N 0.000 description 1
• 102100032912 CD44 antigen Human genes 0.000 description 1
• 241000252983 Caecum Species 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 206010007134 Candida infections Diseases 0.000 description 1
• 206010007559 Cardiac failure congestive Diseases 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
• 206010051288 Central nervous system inflammation Diseases 0.000 description 1
• KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
• 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
• WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 208000010200 Cockayne syndrome Diseases 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 206010054002 Congenital syphilitic osteochondritis Diseases 0.000 description 1
• 206010010904 Convulsion Diseases 0.000 description 1
• 101800000414 Corticotropin Proteins 0.000 description 1
• 241000557626 Corvus corax Species 0.000 description 1
• XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
• 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
• 208000003164 Diplopia Diseases 0.000 description 1
• 206010073508 Drug reaction with eosinophilia and systemic symptoms Diseases 0.000 description 1
• 208000032274 Encephalopathy Diseases 0.000 description 1
• 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
• 206010015150 Erythema Diseases 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 108700024394 Exon Proteins 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• 206010016717 Fistula Diseases 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 230000005526 G1 to G0 transition Effects 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 208000007465 Giant cell arteritis Diseases 0.000 description 1
• 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
• 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
• 101000635799 Homo sapiens Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Proteins 0.000 description 1
• 208000008454 Hyperhidrosis Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• 102000012355 Integrin beta1 Human genes 0.000 description 1
• 108010022222 Integrin beta1 Proteins 0.000 description 1
• 108010005716 Interferon beta-1a Proteins 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• 206010022653 Intestinal haemorrhages Diseases 0.000 description 1
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
• 206010023203 Joint destruction Diseases 0.000 description 1
• 239000007836 KH2PO4 Substances 0.000 description 1
• 208000028226 Krabbe disease Diseases 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• 206010025327 Lymphopenia Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 101710085938 Matrix protein Proteins 0.000 description 1
• 101710127721 Membrane protein Proteins 0.000 description 1
• 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 1
• FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
• 208000019695 Migraine disease Diseases 0.000 description 1
• 206010072927 Mucolipidosis type I Diseases 0.000 description 1
• 101100341510 Mus musculus Itgal gene Proteins 0.000 description 1
• 208000007101 Muscle Cramp Diseases 0.000 description 1
• 102000047918 Myelin Basic Human genes 0.000 description 1
• 101710107068 Myelin basic protein Proteins 0.000 description 1
• 102100026784 Myelin proteolipid protein Human genes 0.000 description 1
• 102000017099 Myelin-Associated Glycoprotein Human genes 0.000 description 1
• 108010013731 Myelin-Associated Glycoprotein Proteins 0.000 description 1
• 208000009525 Myocarditis Diseases 0.000 description 1
• 102100032965 Myomesin-2 Human genes 0.000 description 1
• UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
• HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 206010029113 Neovascularisation Diseases 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• 208000014060 Niemann-Pick disease Diseases 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 208000007027 Oral Candidiasis Diseases 0.000 description 1
• 206010033892 Paraplegia Diseases 0.000 description 1
• 208000031481 Pathologic Constriction Diseases 0.000 description 1
• 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 201000011252 Phenylketonuria Diseases 0.000 description 1
• 108010004729 Phycoerythrin Proteins 0.000 description 1
• 206010035664 Pneumonia Diseases 0.000 description 1
• 206010036030 Polyarthritis Diseases 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
• 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
• 206010036774 Proctitis Diseases 0.000 description 1
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
• 229910019020 PtO2 Inorganic materials 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• 206010037714 Quadriplegia Diseases 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 208000005587 Refsum Disease Diseases 0.000 description 1
• 208000033464 Reiter syndrome Diseases 0.000 description 1
• 241000219061 Rheum Species 0.000 description 1
• 208000025747 Rheumatic disease Diseases 0.000 description 1
• 206010039085 Rhinitis allergic Diseases 0.000 description 1
• 229910006069 SO3H Inorganic materials 0.000 description 1
• 208000013608 Salla disease Diseases 0.000 description 1
• 208000034189 Sclerosis Diseases 0.000 description 1
• 206010040026 Sensory disturbance Diseases 0.000 description 1
• 229920001800 Shellac Polymers 0.000 description 1
• 208000000828 Sialic Acid Storage Disease Diseases 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• 208000006045 Spondylarthropathies Diseases 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 201000009594 Systemic Scleroderma Diseases 0.000 description 1
• 206010042953 Systemic sclerosis Diseases 0.000 description 1
• 208000022292 Tay-Sachs disease Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 241000287411 Turdidae Species 0.000 description 1
• 206010046851 Uveitis Diseases 0.000 description 1
• 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
• 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
• 206010047115 Vasculitis Diseases 0.000 description 1
• 206010047513 Vision blurred Diseases 0.000 description 1
• 239000002250 absorbent Substances 0.000 description 1
• 230000002745 absorbent Effects 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 229940081735 acetylcellulose Drugs 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
• 230000009798 acute exacerbation Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 102000019997 adhesion receptor Human genes 0.000 description 1
• 108010013985 adhesion receptor Proteins 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• 208000030597 adult Refsum disease Diseases 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 150000003973 alkyl amines Chemical class 0.000 description 1
• 125000005431 alkyl carboxamide group Chemical group 0.000 description 1
• 150000001350 alkyl halides Chemical class 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• 201000010105 allergic rhinitis Diseases 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 230000000961 alloantigen Effects 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 229940037003 alum Drugs 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 210000001132 alveolar macrophage Anatomy 0.000 description 1
• 239000000908 ammonium hydroxide Substances 0.000 description 1
• 206010002156 anal fistula Diseases 0.000 description 1
• 238000012435 analytical chromatography Methods 0.000 description 1
• 210000003484 anatomy Anatomy 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 230000003466 anti-cipated effect Effects 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 230000000845 anti-microbial effect Effects 0.000 description 1
• 210000000709 aorta Anatomy 0.000 description 1
• 239000003125 aqueous solvent Substances 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 229960003121 arginine Drugs 0.000 description 1
• 150000004982 aromatic amines Chemical class 0.000 description 1
• 230000008321 arterial blood flow Effects 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 229910052788 barium Inorganic materials 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
• 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
• 229960003237 betaine Drugs 0.000 description 1
• 239000003181 biological factor Substances 0.000 description 1
• 239000012472 biological sample Substances 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 238000009534 blood test Methods 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 238000010322 bone marrow transplantation Methods 0.000 description 1
• 230000024279 bone resorption Effects 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 210000005013 brain tissue Anatomy 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• 230000005587 bubbling Effects 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• GGGWIAMJVIYCGA-UHFFFAOYSA-N butan-2-yl benzenecarboperoxoate Chemical class CCC(C)OOC(=O)C1=CC=CC=C1 GGGWIAMJVIYCGA-UHFFFAOYSA-N 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 229960001948 caffeine Drugs 0.000 description 1
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 239000000378 calcium silicate Substances 0.000 description 1
• 229910052918 calcium silicate Inorganic materials 0.000 description 1
• 229960003340 calcium silicate Drugs 0.000 description 1
• 235000012241 calcium silicate Nutrition 0.000 description 1
• OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
• 201000003984 candidiasis Diseases 0.000 description 1
• OKSMUOUAYBRFFR-UHFFFAOYSA-N carbamic acid 2-nitropyrimidine Chemical compound NC(O)=O.[O-][N+](=O)C1=NC=CC=N1 OKSMUOUAYBRFFR-UHFFFAOYSA-N 0.000 description 1
• WDRLHTSOCBOOOY-UHFFFAOYSA-N carbamic acid;n-propan-2-ylpyrimidin-2-amine Chemical compound NC(O)=O.CC(C)NC1=NC=CC=N1 WDRLHTSOCBOOOY-UHFFFAOYSA-N 0.000 description 1
• FTGSIORLSFWWPI-UHFFFAOYSA-N carbamic acid;pyrimidin-2-amine Chemical compound NC(O)=O.NC1=NC=CC=N1 FTGSIORLSFWWPI-UHFFFAOYSA-N 0.000 description 1
• BMGQDNIDDQSVDQ-UHFFFAOYSA-N carbamic acid;pyrimidine Chemical compound NC(O)=O.C1=CN=CN=C1 BMGQDNIDDQSVDQ-UHFFFAOYSA-N 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 150000003857 carboxamides Chemical class 0.000 description 1
• 238000012754 cardiac puncture Methods 0.000 description 1
• 210000004970 cd4 cell Anatomy 0.000 description 1
• 210000004534 cecum Anatomy 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 239000006285 cell suspension Substances 0.000 description 1
• 229920002301 cellulose acetate Polymers 0.000 description 1
• 231100000153 central nervous system (CNS) toxicity Toxicity 0.000 description 1
• 208000015114 central nervous system disease Diseases 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 210000001638 cerebellum Anatomy 0.000 description 1
• 206010008118 cerebral infarction Diseases 0.000 description 1
• 210000004289 cerebral ventricle Anatomy 0.000 description 1
• 229960000541 cetyl alcohol Drugs 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 238000000451 chemical ionisation Methods 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 239000005482 chemotactic factor Substances 0.000 description 1
• 238000010568 chiral column chromatography Methods 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 208000023819 chronic asthma Diseases 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 230000006020 chronic inflammation Effects 0.000 description 1
• 235000013985 cinnamic acid Nutrition 0.000 description 1
• 229930016911 cinnamic acid Natural products 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• 229940069078 citric acid / sodium citrate Drugs 0.000 description 1
• 239000003240 coconut oil Substances 0.000 description 1
• 235000019864 coconut oil Nutrition 0.000 description 1
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
• 239000000084 colloidal system Substances 0.000 description 1
• 230000008951 colonic inflammation Effects 0.000 description 1
• 238000012875 competitive assay Methods 0.000 description 1
• 230000009137 competitive binding Effects 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 239000008139 complexing agent Substances 0.000 description 1
• 239000002361 compost Substances 0.000 description 1
• 229940125773 compound 10 Drugs 0.000 description 1
• 229940125797 compound 12 Drugs 0.000 description 1
• 229940125898 compound 5 Drugs 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 239000002285 corn oil Substances 0.000 description 1
• 235000005687 corn oil Nutrition 0.000 description 1
• IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
• 229960000258 corticotropin Drugs 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 230000009260 cross reactivity Effects 0.000 description 1
• 239000013058 crude material Substances 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 230000001186 cumulative effect Effects 0.000 description 1
• HASGOCLZFTZSTN-UHFFFAOYSA-N cyclohexane;hexane Chemical class CCCCCC.C1CCCCC1 HASGOCLZFTZSTN-UHFFFAOYSA-N 0.000 description 1
• 238000007405 data analysis Methods 0.000 description 1
• 238000000354 decomposition reaction Methods 0.000 description 1
• 238000005034 decoration Methods 0.000 description 1
• 201000001981 dermatomyositis Diseases 0.000 description 1
• 150000008050 dialkyl sulfates Chemical class 0.000 description 1
• 125000005265 dialkylamine group Chemical group 0.000 description 1
• 125000005432 dialkylcarboxamide group Chemical group 0.000 description 1
• 125000005266 diarylamine group Chemical group 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
• 125000006371 dihalo methyl group Chemical group 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
• MSJMDZAOKORVFC-UAIGNFCESA-L disodium maleate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C/C([O-])=O MSJMDZAOKORVFC-UAIGNFCESA-L 0.000 description 1
• 210000004921 distal colon Anatomy 0.000 description 1
• 230000009429 distress Effects 0.000 description 1
• 239000013583 drug formulation Substances 0.000 description 1
• 238000001035 drying Methods 0.000 description 1
• 210000001198 duodenum Anatomy 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 239000008157 edible vegetable oil Substances 0.000 description 1
• 229920001971 elastomer Polymers 0.000 description 1
• 210000001513 elbow Anatomy 0.000 description 1
• 238000000132 electrospray ionisation Methods 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 201000002491 encephalomyelitis Diseases 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 208000030172 endocrine system disease Diseases 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 239000002702 enteric coating Substances 0.000 description 1
• 238000009505 enteric coating Methods 0.000 description 1
• 239000012055 enteric layer Substances 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
• 230000002327 eosinophilic effect Effects 0.000 description 1
• 230000001667 episodic effect Effects 0.000 description 1
• 210000003238 esophagus Anatomy 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
• 230000006203 ethylation Effects 0.000 description 1
• 238000006200 ethylation reaction Methods 0.000 description 1
• 229940012017 ethylenediamine Drugs 0.000 description 1
• 230000003203 everyday effect Effects 0.000 description 1
• 230000005713 exacerbation Effects 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 230000002550 fecal effect Effects 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 230000003890 fistula Effects 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 235000020375 flavoured syrup Nutrition 0.000 description 1
• 239000013305 flexible fiber Substances 0.000 description 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 235000011087 fumaric acid Nutrition 0.000 description 1
• LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 229940014259 gelatin Drugs 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 239000012362 glacial acetic acid Substances 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 229960002743 glutamine Drugs 0.000 description 1
• 150000002337 glycosamines Chemical class 0.000 description 1
• 208000010758 granulomatous inflammation Diseases 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 125000004969 haloethyl group Chemical group 0.000 description 1
• 229910052736 halogen Inorganic materials 0.000 description 1
• 150000002367 halogens Chemical class 0.000 description 1
• 125000004970 halomethyl group Chemical group 0.000 description 1
• 210000004247 hand Anatomy 0.000 description 1
• 238000013038 hand mixing Methods 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 210000002216 heart Anatomy 0.000 description 1
• 210000005003 heart tissue Anatomy 0.000 description 1
• 208000014951 hematologic disease Diseases 0.000 description 1
• 208000018706 hematopoietic system disease Diseases 0.000 description 1
• IZZWJPQHPPRVLP-UHFFFAOYSA-N hexane;2-methoxy-2-methylpropane Chemical compound CCCCCC.COC(C)(C)C IZZWJPQHPPRVLP-UHFFFAOYSA-N 0.000 description 1
• 210000001320 hippocampus Anatomy 0.000 description 1
• 229960001340 histamine Drugs 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 229960002885 histidine Drugs 0.000 description 1
• 238000007489 histopathology method Methods 0.000 description 1
• 239000008240 homogeneous mixture Substances 0.000 description 1
• XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical group [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 230000037315 hyperhidrosis Effects 0.000 description 1
• 239000000819 hypertonic solution Substances 0.000 description 1
• 229940021223 hypertonic solution Drugs 0.000 description 1
• 150000002466 imines Chemical class 0.000 description 1
• 238000007654 immersion Methods 0.000 description 1
• 230000006058 immune tolerance Effects 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 238000010874 in vitro model Methods 0.000 description 1
• 239000011261 inert gas Substances 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 239000005550 inflammation mediator Substances 0.000 description 1
• 208000008527 inflammatory bowel disease 15 Diseases 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 230000004941 influx Effects 0.000 description 1
• 239000003978 infusion fluid Substances 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 239000003999 initiator Substances 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 230000005732 intercellular adhesion Effects 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 229960004461 interferon beta-1a Drugs 0.000 description 1
• 229940047122 interleukins Drugs 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 210000004347 intestinal mucosa Anatomy 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 229960002725 isoflurane Drugs 0.000 description 1
• JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
• ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 210000002414 leg Anatomy 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 208000036546 leukodystrophy Diseases 0.000 description 1
• 150000002617 leukotrienes Chemical class 0.000 description 1
• 229960004194 lidocaine Drugs 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 238000004811 liquid chromatography Methods 0.000 description 1
• 239000011344 liquid material Substances 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 229960003646 lysine Drugs 0.000 description 1
• 229910001629 magnesium chloride Inorganic materials 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 229960002510 mandelic acid Drugs 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
• UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• 229960004584 methylprednisolone Drugs 0.000 description 1
• 238000000386 microscopy Methods 0.000 description 1
• 206010027599 migraine Diseases 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
• 235000019796 monopotassium phosphate Nutrition 0.000 description 1
• 235000016337 monopotassium tartrate Nutrition 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 210000004877 mucosa Anatomy 0.000 description 1
• 210000003007 myelin sheath Anatomy 0.000 description 1
• 230000023105 myelination Effects 0.000 description 1
• 230000002107 myocardial effect Effects 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• 230000007830 nerve conduction Effects 0.000 description 1
• 210000004126 nerve fiber Anatomy 0.000 description 1
• 210000001178 neural stem cell Anatomy 0.000 description 1
• 230000009251 neurologic dysfunction Effects 0.000 description 1
• 230000004776 neurological deficiency Effects 0.000 description 1
• 230000007971 neurological deficit Effects 0.000 description 1
• 208000015015 neurological dysfunction Diseases 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 210000004248 oligodendroglia Anatomy 0.000 description 1
• 238000005457 optimization Methods 0.000 description 1
• 229940124624 oral corticosteroid Drugs 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 208000014965 pancolitis Diseases 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 230000001314 paroxysmal effect Effects 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 229960001412 pentobarbital Drugs 0.000 description 1
• 208000008494 pericarditis Diseases 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• FYQGHJHASJALLI-UHFFFAOYSA-N phenyl pyrrolidine-1-carboxylate Chemical compound C1CCCN1C(=O)OC1=CC=CC=C1 FYQGHJHASJALLI-UHFFFAOYSA-N 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• 150000003016 phosphoric acids Chemical class 0.000 description 1
• 235000002651 pink gum Nutrition 0.000 description 1
• 244000087877 pink gum Species 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 208000030428 polyarticular arthritis Diseases 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• 238000010837 poor prognosis Methods 0.000 description 1
• 230000008092 positive effect Effects 0.000 description 1
• 230000002980 postoperative effect Effects 0.000 description 1
• KYKNRZGSIGMXFH-ZVGUSBNCSA-M potassium bitartrate Chemical compound [K+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O KYKNRZGSIGMXFH-ZVGUSBNCSA-M 0.000 description 1
• GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
• 229940086065 potassium hydrogentartrate Drugs 0.000 description 1
• 239000001472 potassium tartrate Substances 0.000 description 1
• 229940111695 potassium tartrate Drugs 0.000 description 1
• 235000011005 potassium tartrates Nutrition 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
• 229960000244 procainamide Drugs 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 206010036784 proctocolitis Diseases 0.000 description 1
• 208000017048 proctosigmoiditis Diseases 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• LJZPPWWHKPGCHS-UHFFFAOYSA-N propargyl chloride Chemical compound ClCC#C LJZPPWWHKPGCHS-UHFFFAOYSA-N 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• 150000003180 prostaglandins Chemical class 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
• 230000000541 pulsatile effect Effects 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 1
• 150000003230 pyrimidines Chemical class 0.000 description 1
• 229940107700 pyruvic acid Drugs 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 239000000941 radioactive substance Substances 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 239000000376 reactant Substances 0.000 description 1
• 230000007420 reactivation Effects 0.000 description 1
• 208000002574 reactive arthritis Diseases 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 238000010992 reflux Methods 0.000 description 1
• QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
• 230000029058 respiratory gaseous exchange Effects 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 230000000552 rheumatic effect Effects 0.000 description 1
• 230000000630 rising effect Effects 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 239000004576 sand Substances 0.000 description 1
• 238000005488 sandblasting Methods 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 230000037390 scarring Effects 0.000 description 1
• 238000007789 sealing Methods 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 239000012056 semi-solid material Substances 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 239000004208 shellac Substances 0.000 description 1
• 229940113147 shellac Drugs 0.000 description 1
• ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
• 235000013874 shellac Nutrition 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
• 239000004299 sodium benzoate Substances 0.000 description 1
• 235000010234 sodium benzoate Nutrition 0.000 description 1
• 229910000033 sodium borohydride Inorganic materials 0.000 description 1
• 239000012279 sodium borohydride Substances 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000008354 sodium chloride injection Substances 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
• 159000000000 sodium salts Chemical class 0.000 description 1
• IZUPJOYPPLEPGM-UHFFFAOYSA-M sodium;hydron;phthalate Chemical compound [Na+].OC(=O)C1=CC=CC=C1C([O-])=O IZUPJOYPPLEPGM-UHFFFAOYSA-M 0.000 description 1
• 239000011343 solid material Substances 0.000 description 1
• 239000002594 sorbent Substances 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 235000010356 sorbitol Nutrition 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 238000004611 spectroscopical analysis Methods 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 201000005671 spondyloarthropathy Diseases 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 238000007447 staining method Methods 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 238000011272 standard treatment Methods 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 230000036262 stenosis Effects 0.000 description 1
• 208000037804 stenosis Diseases 0.000 description 1
• 230000000707 stereoselective effect Effects 0.000 description 1
• 239000012058 sterile packaged powder Substances 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 208000003265 stomatitis Diseases 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 125000005017 substituted alkenyl group Chemical group 0.000 description 1
• 125000000547 substituted alkyl group Chemical group 0.000 description 1
• 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 210000002437 synoviocyte Anatomy 0.000 description 1
• 229940066769 systemic antihistamines substituted alkylamines Drugs 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 239000007916 tablet composition Substances 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 239000008399 tap water Substances 0.000 description 1
• 235000020679 tap water Nutrition 0.000 description 1
• 210000004876 tela submucosa Anatomy 0.000 description 1
• 206010043207 temporal arteritis Diseases 0.000 description 1
• 150000003512 tertiary amines Chemical class 0.000 description 1
• 229960004559 theobromine Drugs 0.000 description 1
• 206010043778 thyroiditis Diseases 0.000 description 1
• 229950003937 tolonium Drugs 0.000 description 1
• HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
• 239000008181 tonicity modifier Substances 0.000 description 1
• 238000002691 topical anesthesia Methods 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 230000037317 transdermal delivery Effects 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• 238000011277 treatment modality Methods 0.000 description 1
• 125000005270 trialkylamine group Chemical group 0.000 description 1
• 125000005259 triarylamine group Chemical group 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 125000004953 trihalomethyl group Chemical group 0.000 description 1
• YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 238000001665 trituration Methods 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 210000003606 umbilical vein Anatomy 0.000 description 1
• 238000009827 uniform distribution Methods 0.000 description 1
• 238000013022 venting Methods 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 238000003260 vortexing Methods 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 239000012224 working solution Substances 0.000 description 1
• 210000000707 wrist Anatomy 0.000 description 1
• 239000000230 xanthan gum Substances 0.000 description 1
• 235000010493 xanthan gum Nutrition 0.000 description 1
• 229920001285 xanthan gum Polymers 0.000 description 1
• 229940082509 xanthan gum Drugs 0.000 description 1